Impact of Blood Pressure Visit-to-Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation : Subanalysis of the J-RHYTHM Registry
Background Blood pressure (BP) variability has reportedly been a risk factor for various clinical events. To clarify the influence of BP visit-to-visit variability on adverse events in patients with nonvalvular atrial fibrillation, a post hoc analysis of the J-RHYTHM Registry was performed. Methods and Results Of 7406 outpatients with nonvalvular atrial fibrillation from 158 institutions, 7226 (age, 69.7±9.9 years; men, 70.7%), in whom BP was measured 4 times or more (14.6±5.0 times) during the 2-year follow-up period or until occurrence of an event, constituted the study group. SD and coefficient of variation of BP values were calculated as BP variability. Thromboembolism, major hemorrhage, and all-cause death occurred in 110 (1.5%), 121 (1.7%), and 168 (2.3%) patients, respectively. When patients were divided into quartiles of systolic BP-SD (<8.20, 8.20-10.49, 10.50-13.19, and ≥13.20 mm Hg), hazard ratios (HRs) for all adverse events were significantly high in the highest quartile compared with the lowest quartile (HR, 2.00, 95% CI, 1.15-3.49, P=0.015 for thromboembolism; HR, 2.60, 95% CI, 1.36-4.97, P=0.004 for major hemorrhage; and HR, 1.85, 95% CI, 1.11-3.07, P=0.018 for all-cause death) after adjusting for components of the CHA2DS2-VASc score, warfarin and antiplatelet use, atrial fibrillation type, BP measurement times, and others. These findings were consistent when BP-coefficient of variation was used instead of BP-SD. Conclusions Systolic BP visit-to-visit variability was significantly associated with all adverse events in patients with nonvalvular atrial fibrillation. Further studies are needed to clarify the causality between BP variability and adverse outcomes in patients with nonvalvular atrial fibrillation. Registration URL: https://www.umin.ac.jp/ctr/; Unique Identifier: UMIN000001569.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of the American Heart Association - 10(2021), 1 vom: 05. Jan., Seite e018585 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kodani, Eitaro [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.10.2021 Date Revised 18.10.2021 published: Print-Electronic UMIN-CTR: UMIN000001569 Citation Status MEDLINE |
|---|
| doi: |
10.1161/JAHA.120.018585 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319367142 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319367142 | ||
| 003 | DE-627 | ||
| 005 | 20231225171310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/JAHA.120.018585 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1064.xml |
| 035 | |a (DE-627)NLM319367142 | ||
| 035 | |a (NLM)33372541 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kodani, Eitaro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of Blood Pressure Visit-to-Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation |b Subanalysis of the J-RHYTHM Registry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2021 | ||
| 500 | |a Date Revised 18.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UMIN-CTR: UMIN000001569 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background Blood pressure (BP) variability has reportedly been a risk factor for various clinical events. To clarify the influence of BP visit-to-visit variability on adverse events in patients with nonvalvular atrial fibrillation, a post hoc analysis of the J-RHYTHM Registry was performed. Methods and Results Of 7406 outpatients with nonvalvular atrial fibrillation from 158 institutions, 7226 (age, 69.7±9.9 years; men, 70.7%), in whom BP was measured 4 times or more (14.6±5.0 times) during the 2-year follow-up period or until occurrence of an event, constituted the study group. SD and coefficient of variation of BP values were calculated as BP variability. Thromboembolism, major hemorrhage, and all-cause death occurred in 110 (1.5%), 121 (1.7%), and 168 (2.3%) patients, respectively. When patients were divided into quartiles of systolic BP-SD (<8.20, 8.20-10.49, 10.50-13.19, and ≥13.20 mm Hg), hazard ratios (HRs) for all adverse events were significantly high in the highest quartile compared with the lowest quartile (HR, 2.00, 95% CI, 1.15-3.49, P=0.015 for thromboembolism; HR, 2.60, 95% CI, 1.36-4.97, P=0.004 for major hemorrhage; and HR, 1.85, 95% CI, 1.11-3.07, P=0.018 for all-cause death) after adjusting for components of the CHA2DS2-VASc score, warfarin and antiplatelet use, atrial fibrillation type, BP measurement times, and others. These findings were consistent when BP-coefficient of variation was used instead of BP-SD. Conclusions Systolic BP visit-to-visit variability was significantly associated with all adverse events in patients with nonvalvular atrial fibrillation. Further studies are needed to clarify the causality between BP variability and adverse outcomes in patients with nonvalvular atrial fibrillation. Registration URL: https://www.umin.ac.jp/ctr/; Unique Identifier: UMIN000001569 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a blood pressure | |
| 650 | 4 | |a major hemorrhage | |
| 650 | 4 | |a thromboembolism | |
| 650 | 4 | |a variability | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 700 | 1 | |a Inoue, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Atarashi, Hirotsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Okumura, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashita, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Otsuka, Toshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Origasa, Hideki |e verfasserin |4 aut | |
| 700 | 0 | |a J‐RHYTHM Registry Investigators * |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, H |e investigator |4 oth | |
| 700 | 1 | |a Okumura, K |e investigator |4 oth | |
| 700 | 1 | |a Atarashi, H |e investigator |4 oth | |
| 700 | 1 | |a Yamashita, T |e investigator |4 oth | |
| 700 | 1 | |a Sakurai, M |e investigator |4 oth | |
| 700 | 1 | |a Kawamura, Y |e investigator |4 oth | |
| 700 | 1 | |a Okumura, K |e investigator |4 oth | |
| 700 | 1 | |a Kubota, I |e investigator |4 oth | |
| 700 | 1 | |a Kaneko, Y |e investigator |4 oth | |
| 700 | 1 | |a Matsumoto, K |e investigator |4 oth | |
| 700 | 1 | |a Ogawa, S |e investigator |4 oth | |
| 700 | 1 | |a Atarashi, H |e investigator |4 oth | |
| 700 | 1 | |a Yamashita, T |e investigator |4 oth | |
| 700 | 1 | |a Inoue, H |e investigator |4 oth | |
| 700 | 1 | |a Aizawa, Y |e investigator |4 oth | |
| 700 | 1 | |a Kodama, I |e investigator |4 oth | |
| 700 | 1 | |a Watanabe, E |e investigator |4 oth | |
| 700 | 1 | |a Koretsune, Y |e investigator |4 oth | |
| 700 | 1 | |a Okuyama, Y |e investigator |4 oth | |
| 700 | 1 | |a Shimizu, A |e investigator |4 oth | |
| 700 | 1 | |a Igawa, O |e investigator |4 oth | |
| 700 | 1 | |a Bando, S |e investigator |4 oth | |
| 700 | 1 | |a Fukatani, M |e investigator |4 oth | |
| 700 | 1 | |a Saikawa, T |e investigator |4 oth | |
| 700 | 1 | |a Chishaki, A |e investigator |4 oth | |
| 700 | 1 | |a Origasa, H |e investigator |4 oth | |
| 700 | 1 | |a Kato, N |e investigator |4 oth | |
| 700 | 1 | |a Kanda, K |e investigator |4 oth | |
| 700 | 1 | |a Kato, J |e investigator |4 oth | |
| 700 | 1 | |a Obata, H |e investigator |4 oth | |
| 700 | 1 | |a Aoki, M |e investigator |4 oth | |
| 700 | 1 | |a Honda, H |e investigator |4 oth | |
| 700 | 1 | |a Konta, Y |e investigator |4 oth | |
| 700 | 1 | |a Hatayama, T |e investigator |4 oth | |
| 700 | 1 | |a Abe, Y |e investigator |4 oth | |
| 700 | 1 | |a Terata, K |e investigator |4 oth | |
| 700 | 1 | |a Yagi, T |e investigator |4 oth | |
| 700 | 1 | |a Ishida, A |e investigator |4 oth | |
| 700 | 1 | |a Komatsu, T |e investigator |4 oth | |
| 700 | 1 | |a Tachibana, H |e investigator |4 oth | |
| 700 | 1 | |a Suzuki, H |e investigator |4 oth | |
| 700 | 1 | |a Kamiyama, Y |e investigator |4 oth | |
| 700 | 1 | |a Watanabe, T |e investigator |4 oth | |
| 700 | 1 | |a Oguma, M |e investigator |4 oth | |
| 700 | 1 | |a Itoh, M |e investigator |4 oth | |
| 700 | 1 | |a Hirono, O |e investigator |4 oth | |
| 700 | 1 | |a Tsunoda, Y |e investigator |4 oth | |
| 700 | 1 | |a Ikeda, K |e investigator |4 oth | |
| 700 | 1 | |a Kanaya, T |e investigator |4 oth | |
| 700 | 1 | |a Sakurai, K |e investigator |4 oth | |
| 700 | 1 | |a Sukekawa, H |e investigator |4 oth | |
| 700 | 1 | |a Nakada, S |e investigator |4 oth | |
| 700 | 1 | |a Itoh, T |e investigator |4 oth | |
| 700 | 1 | |a Tange, S |e investigator |4 oth | |
| 700 | 1 | |a Manita, M |e investigator |4 oth | |
| 700 | 1 | |a Ohta, M |e investigator |4 oth | |
| 700 | 1 | |a Eguma, H |e investigator |4 oth | |
| 700 | 1 | |a Kato, R |e investigator |4 oth | |
| 700 | 1 | |a Endo, Y |e investigator |4 oth | |
| 700 | 1 | |a Ogino, T |e investigator |4 oth | |
| 700 | 1 | |a Yamazaki, M |e investigator |4 oth | |
| 700 | 1 | |a Kanki, H |e investigator |4 oth | |
| 700 | 1 | |a Uchida, M |e investigator |4 oth | |
| 700 | 1 | |a Miyanaga, S |e investigator |4 oth | |
| 700 | 1 | |a Shibayama, K |e investigator |4 oth | |
| 700 | 1 | |a Toratani, N |e investigator |4 oth | |
| 700 | 1 | |a Kojima, T |e investigator |4 oth | |
| 700 | 1 | |a Ichikawa, M |e investigator |4 oth | |
| 700 | 1 | |a Saito, M |e investigator |4 oth | |
| 700 | 1 | |a Umeda, Y |e investigator |4 oth | |
| 700 | 1 | |a Sawanobori, T |e investigator |4 oth | |
| 700 | 1 | |a Sohara, H |e investigator |4 oth | |
| 700 | 1 | |a Okubo, S |e investigator |4 oth | |
| 700 | 1 | |a Okubo, T |e investigator |4 oth | |
| 700 | 1 | |a Tokunaga, T |e investigator |4 oth | |
| 700 | 1 | |a Kuboyama, O |e investigator |4 oth | |
| 700 | 1 | |a Ito, H |e investigator |4 oth | |
| 700 | 1 | |a Kitahara, Y |e investigator |4 oth | |
| 700 | 1 | |a Sagara, K |e investigator |4 oth | |
| 700 | 1 | |a Satoh, T |e investigator |4 oth | |
| 700 | 1 | |a Kodani, E |e investigator |4 oth | |
| 700 | 1 | |a Sugi, K |e investigator |4 oth | |
| 700 | 1 | |a Kobayashi, Y |e investigator |4 oth | |
| 700 | 1 | |a Higashi, Y |e investigator |4 oth | |
| 700 | 1 | |a Katoh, T |e investigator |4 oth | |
| 700 | 1 | |a Hirayama, Y |e investigator |4 oth | |
| 700 | 1 | |a Matsumoto, N |e investigator |4 oth | |
| 700 | 1 | |a Takano, M |e investigator |4 oth | |
| 700 | 1 | |a Ikeda, T |e investigator |4 oth | |
| 700 | 1 | |a Yusu, S |e investigator |4 oth | |
| 700 | 1 | |a Niwano, S |e investigator |4 oth | |
| 700 | 1 | |a Nakazato, Y |e investigator |4 oth | |
| 700 | 1 | |a Kawano, Y |e investigator |4 oth | |
| 700 | 1 | |a Sumiyoshi, M |e investigator |4 oth | |
| 700 | 1 | |a Hagiwara, N |e investigator |4 oth | |
| 700 | 1 | |a Murasaki, K |e investigator |4 oth | |
| 700 | 1 | |a Mitamura, H |e investigator |4 oth | |
| 700 | 1 | |a Nakagawa, S |e investigator |4 oth | |
| 700 | 1 | |a Okishige, K |e investigator |4 oth | |
| 700 | 1 | |a Azegami, K |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Heart Association |d 2012 |g 10(2021), 1 vom: 05. Jan., Seite e018585 |w (DE-627)NLM222412712 |x 2047-9980 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:1 |g day:05 |g month:01 |g pages:e018585 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/JAHA.120.018585 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 1 |b 05 |c 01 |h e018585 | ||